MK-3475 + Bevacizumab + MK-3475 + Bevacizumab
Phase 1/2Completed 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Clear Cell Renal Carcinoma
Conditions
Clear Cell Renal Carcinoma
Trial Timeline
Mar 1, 2015 → Dec 5, 2019
NCT ID
NCT02348008About MK-3475 + Bevacizumab + MK-3475 + Bevacizumab
MK-3475 + Bevacizumab + MK-3475 + Bevacizumab is a phase 1/2 stage product being developed by Merck for Clear Cell Renal Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02348008. Target conditions include Clear Cell Renal Carcinoma.
What happened to similar drugs?
3 of 13 similar drugs in Clear Cell Renal Carcinoma were approved
Approved (3) Terminated (1) Active (9)
✅nebulized albuterol (2.5 mg/3ml/dose) + nebulized levalbuterol (1.25 mg/3ml/dose) + nebulized placebo (3ml/dose)Sumitomo PharmaApproved
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02348008 | Phase 1/2 | Completed |
Competing Products
20 competing products in Clear Cell Renal Carcinoma